Back to Journals Vascular Health and Risk Management Volume 12 SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Authors Gurgle H, White K, McAdam-Marx C Received 14 November 2015 Accepted for publication 11 March 2016 Published 4 June 2016 Volume 2016:12 Pages 239249 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 5 Editor who approved publication: Dr Daniel Duprez Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone
A great product for enhancing both scalp and hair health
The real-world GLP-1 boost from a morning collagen smoothie, while biochemically real, likely falls well below the threshold needed for clinically significant appetite suppression or weight loss outcomes
IGF-1 is released mainly from the liver and improves insulin sensitivity by suppression of insulin secretion, in turn leading to augmented lipolysis in adipose tissue and promotion of NEFA use in muscle and liver
For example, a pulse survey of our client law firms in August found only 35% of those firms offering coverage today
The sixth vital sign: what reproduction tells us about overall health
.png)
